A Lipid Hypothesis: Prediction, Observation and the Triglyceride/HDL Gap

References

• Shepherd J., Cobbe S. M., Ford I. Prevention of coronary heart disease with pravastatin in men with hypercholesterolaemia. N. Engl. J. Med. 1995; 333: 1301, 13071. Shepherd J., Cobbe S. M., Ford I. Prevention of coronary heart disease with pravastatin in men with hypercholesterolaemia. N. Engl. J. Med. 1995; 333: 1301, 1307
   PubMed Web of Science ®Google Scholar
• Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study. Lancet 1994; 344: 1383, 13892. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study. Lancet 1994; 344: 1383, 1389
   PubMed Web of Science ®Google Scholar
• Wilt T. J., Davis B., Meyers D. G. Prevalence and correlates of symptomatic peripheral atherosclerosis in individuals with coronary heart disease and cholesterol levels less than 240mg/dl; baseline results from the cholesterol and recurrent events (CARE) study. Angiology 1996; 47: 533, 5413. Wilt T. J., Davis B., Meyers D. G. Prevalence and correlates of symptomatic peripheral atherosclerosis in individuals with coronary heart disease and cholesterol levels less than 240mg/dl; baseline results from the cholesterol and recurrent events (CARE) study. Angiology 1996; 47: 533, 541
   PubMed Web of Science ®Google Scholar
• Design rationale and baseline characteristics of the prospective pravastatin pooling (PPP) project - a combined analysis of three large-scale randomised trials: long-term intervention with pravastatin in ischemic disease (LIPID), cholesterol and recurrent events (CARE), and West of Scotland Coronary Prevention Study (WOSCOPS). Am. J. Cardiol., 76: 899, 9054. Design rationale and baseline characteristics of the prospective pravastatin pooling (PPP) project - a combined analysis of three large-scale randomised trials: long-term intervention with pravastatin in ischemic disease (LIPID), cholesterol and recurrent events (CARE), and West of Scotland Coronary Prevention Study (WOSCOPS). Am. J. Cardiol., 76: 899, 905
   PubMed Web of Science ®Google Scholar
• The Pravastatin Multinational Study Group for Cardiac Risk Patients. Effects of pravastatin in patients with serum total cholesterol levels from 5.2 to 7.8mmol/l plus two additional atherosclerotic risk factors. Am. J. Cardiol. 1993; 72: 1031, 10375. The Pravastatin Multinational Study Group for Cardiac Risk Patients. Effects of pravastatin in patients with serum total cholesterol levels from 5.2 to 7.8mmol/l plus two additional atherosclerotic risk factors. Am. J. Cardiol. 1993; 72: 1031, 1037
   PubMed Web of Science ®Google Scholar
• Assmann G., Schulte H., von Eckardstein A. Hyper-triglyceridemia and elevated lipoprotein(a) are risk factors for major coronary events in middle-aged men. Am. J. Cardiol. 1996; 77: 1179, 11846. Assmann G., Schulte H., von Eckardstein A. Hyper-triglyceridemia and elevated lipoprotein(a) are risk factors for major coronary events in middle-aged men. Am. J. Cardiol. 1996; 77: 1179, 1184
   PubMed Web of Science ®Google Scholar
• Hodis H. N., Mack W. N. Triglyceride-rich lipoproteins and the progression of coronary artery disease. Curr. Opin. Lipidol. 1995; 269: 505, 5107. Hodis H. N., Mack W. N. Triglyceride-rich lipoproteins and the progression of coronary artery disease. Curr. Opin. Lipidol. 1995; 269: 505, 510
   Google Scholar
• Rader D., Hoeg, Brewer J. M. H. B., Jr. Quantitation of plasma apolipoproteins in the primary and secondary prevention of coronary artery disease. Ann. Intern. Med. 1994; 120: 1012, 10258. Rader D., Hoeg, Brewer J. M. H. B., Jr. Quantitation of plasma apolipoproteins in the primary and secondary prevention of coronary artery disease. Ann. Intern. Med. 1994; 120: 1012, 1025
   PubMed Web of Science ®Google Scholar
• Packard C. Micro News, Lipid Exchanges. Issue No. 1, Oct. The Lipoprotein Consultancy. Los Altos, USA 19959. Packard C. Micro News, Lipid Exchanges. Issue No. 1, Oct. The Lipoprotein Consultancy. Los Altos, USA 1995
   Google Scholar
• Hokanson J., Austin M. A. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol: a meta-analysis of population-based prospective studies. J. Cardiovasc. Risk 1996; 3: 213, 21910. Hokanson J., Austin M. A. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol: a meta-analysis of population-based prospective studies. J. Cardiovasc. Risk 1996; 3: 213, 219
   PubMedGoogle Scholar
• Fuster V., Badimon L., Badimon J.J. The pathogenesis of coronary artery disease and the acute coronary syndrome. N. Engl. J. Med. 1992; 326: 242, 30911. Fuster V., Badimon L., Badimon J.J. The pathogenesis of coronary artery disease and the acute coronary syndrome. N. Engl. J. Med. 1992; 326: 242, 309
   PubMed Web of Science ®Google Scholar
• Brown B. G., Zhao W. Q., Sacco D. E. Lipid lowering and plaque regression: new insights into prevention of plaque disruption and clinical events in coronary disease. Circulation 1993; 87: 1781, 179112. Brown B. G., Zhao W. Q., Sacco D. E. Lipid lowering and plaque regression: new insights into prevention of plaque disruption and clinical events in coronary disease. Circulation 1993; 87: 1781, 1791
   PubMed Web of Science ®Google Scholar
• Law M. R., Wald N. J., Wu T. Systematic understatement of association between serum cholesterol concentration and ischaemic heart disease in observational studies: data from the BUPA study. BMJ 1994; 308: 363, 36613. Law M. R., Wald N. J., Wu T. Systematic understatement of association between serum cholesterol concentration and ischaemic heart disease in observational studies: data from the BUPA study. BMJ 1994; 308: 363, 366
   PubMed Web of Science ®Google Scholar
• The Lipid Research Clinics Program. The lipid research clinics coronary primary prevention trial results. 1. Reduction in the incidence of coronary heart disease. JAMA 1984; 251: 351, 36414. The Lipid Research Clinics Program. The lipid research clinics coronary primary prevention trial results. 1. Reduction in the incidence of coronary heart disease. JAMA 1984; 251: 351, 364
   PubMed Web of Science ®Google Scholar
• Frick M. H., Elo O., Haapa K. Helsinki Heart Study. Primary-prevention trial with gemfibrozil in middle aged men with dyslipidaemia. Safety of treatment, changes in risk factors and incidence of coronary heart disease. N. Engl. J. Med. 1987; 317: 1237, 124515. Frick M. H., Elo O., Haapa K. Helsinki Heart Study. Primary-prevention trial with gemfibrozil in middle aged men with dyslipidaemia. Safety of treatment, changes in risk factors and incidence of coronary heart disease. N. Engl. J. Med. 1987; 317: 1237, 1245
   PubMed Web of Science ®Google Scholar
• Buchwald H., Varco R. L, Matts J. P. Effects of partial ileal bypass on mortality and morbidity from coronary heart disease in patients with hypercholesterolaemia. N. Engl. J. Med. 1990; 329: 946, 95516. Buchwald H., Varco R. L, Matts J. P. Effects of partial ileal bypass on mortality and morbidity from coronary heart disease in patients with hypercholesterolaemia. N. Engl. J. Med. 1990; 329: 946, 955
   Google Scholar
• Carlson L. A., Rosenhamer G. Reduction of mortality in the Stockholm ischaemic disease secondary prevention study by combined treatment with clofibrate and nicotinic acid. Acta Med. Scand. 1988; 223: 405, 41817. Carlson L. A., Rosenhamer G. Reduction of mortality in the Stockholm ischaemic disease secondary prevention study by combined treatment with clofibrate and nicotinic acid. Acta Med. Scand. 1988; 223: 405, 418
   PubMed Web of Science ®Google Scholar
• Sacks R M., Pfeffer M. A., Moye L. A. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N. Engl. J. Med. 1996; 335: 1001, 100918. Sacks R M., Pfeffer M. A., Moye L. A. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N. Engl. J. Med. 1996; 335: 1001, 1009
   PubMed Web of Science ®Google Scholar
• Ericsson C.-G., Hamsten A., Nilsson J. Angiographic assessment of effects of bezafibrate on progression of coronary artery disease in young male post infarction patients. Lancet 1996; 347: 849, 85319. Ericsson C.-G., Hamsten A., Nilsson J. Angiographic assessment of effects of bezafibrate on progression of coronary artery disease in young male post infarction patients. Lancet 1996; 347: 849, 853
   PubMed Web of Science ®Google Scholar
• Bunte T., Hahmann H. W., Hellwig N. Effects of fenofibrate on angiographically examined coronary atherosclerosis and left ventricular function in hypercholesterolemic patients. Atherosclerosis 1993; 98: 127, 13820. Bunte T., Hahmann H. W., Hellwig N. Effects of fenofibrate on angiographically examined coronary atherosclerosis and left ventricular function in hypercholesterolemic patients. Atherosclerosis 1993; 98: 127, 138
   PubMed Web of Science ®Google Scholar
• The MAAS Investigators. Effect of simvastatin on coronary atheroma: the multi centre anti-atheroma study (MAAS). Lancet 1994; 344: 633, 63821. The MAAS Investigators. Effect of simvastatin on coronary atheroma: the multi centre anti-atheroma study (MAAS). Lancet 1994; 344: 633, 638
   PubMed Web of Science ®Google Scholar
• Jukema J. E., Bruschke A. V. G., van Boven A. J. Effect of lipid lowering by pravastatin on progression of coronary artery disease in symptomatic man with normal to moderately elevated serum cholesterol levels: the regression growth evaluation statin study (REGRESS). Circulation 1995; 91: 2528, 2540, on behalf of the REGRESS study group22. Jukema J. E., Bruschke A. V. G., van Boven A. J. Effect of lipid lowering by pravastatin on progression of coronary artery disease in symptomatic man with normal to moderately elevated serum cholesterol levels: the regression growth evaluation statin study (REGRESS). Circulation 1995; 91: 2528, 2540, on behalf of the REGRESS study group
   PubMed Web of Science ®Google Scholar
• Caslake M. J., Packard C. J., Gaw A. Fenofibrate and metabolic heterogeneity in hypercholesterolaemia. Arterioscleros. Thromb. 1993; 13: 702, 70923. Caslake M. J., Packard C. J., Gaw A. Fenofibrate and metabolic heterogeneity in hypercholesterolaemia. Arterioscleros. Thromb. 1993; 13: 702, 709
   PubMedGoogle Scholar
• Gaw A., Packard C. J., Caslake M. J. Effects of ciprofibrate on LDL metabolism in man. Atherosclerosis 1994; 108: 137, 4824. Gaw A., Packard C. J., Caslake M. J. Effects of ciprofibrate on LDL metabolism in man. Atherosclerosis 1994; 108: 137, 48
   PubMed Web of Science ®Google Scholar
• Superko H. R., Krauss R. M., DiRicco R. N. Effect of fluvastatin on low-density lipoprotein peak particle diameter. Am. J. Cardiol. 1997; 80: 78, 8125. Superko H. R., Krauss R. M., DiRicco R. N. Effect of fluvastatin on low-density lipoprotein peak particle diameter. Am. J. Cardiol. 1997; 80: 78, 81
   PubMed Web of Science ®Google Scholar
• Cheung M. C., Austin M. A., Moulin P. Effects of pravastatin on apolipoprotein-specific high density lipoprotein subpopulations and low density lipoprotein subclass phenotypes in patients with primary hypercholesterolaemia. Atherosclerosis 1993; 102: 107, 11926. Cheung M. C., Austin M. A., Moulin P. Effects of pravastatin on apolipoprotein-specific high density lipoprotein subpopulations and low density lipoprotein subclass phenotypes in patients with primary hypercholesterolaemia. Atherosclerosis 1993; 102: 107, 119
   PubMed Web of Science ®Google Scholar
• Jokubaitis L. A. Development and pharmacology of fluvastatin. Br. J. Clin. Pract. Symp. 1996; 77A: 11–15, Suppl27. Jokubaitis L. A. Development and pharmacology of fluvastatin. Br. J. Clin. Pract. Symp. 1996; 77A: 11–15, Suppl
   Google Scholar
• Jokubaitis L. A. Updated clinical safety experience with fluvastatin. Am. J. Cardiol. 1994; 73(14)18D–24D28. Jokubaitis L. A. Updated clinical safety experience with fluvastatin. Am. J. Cardiol. 1994; 73(14)18D–24D
   PubMed Web of Science ®Google Scholar
• Li P. K., Mak T. W., Wang A. Y. The interaction of fluvastatin and cyclosporin A in renal transplant patients. Int. J. Clin. Pharmacol. Ther. 1995; 33(4)246–24829. Li P. K., Mak T. W., Wang A. Y. The interaction of fluvastatin and cyclosporin A in renal transplant patients. Int. J. Clin. Pharmacol. Ther. 1995; 33(4)246–248
   PubMed Web of Science ®Google Scholar
• Farnier M., Leneveur-Ledoux L. French Fluvastatin Study Group. Comparison of fenofibrate monotherapy and two combined fluvastatin/fenofibrate therapy in primary hypercholesterolaemia (abstract). 66th European Atherosclerosis Society Meeting 1996; 210, July 13, Florence30. Farnier M., Leneveur-Ledoux L. French Fluvastatin Study Group. Comparison of fenofibrate monotherapy and two combined fluvastatin/fenofibrate therapy in primary hypercholesterolaemia (abstract). 66th European Atherosclerosis Society Meeting 1996; 210, July 13, Florence
   Google Scholar